A carregar...
Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration
PURPOSE: To assess the feasibility and potential obstacles of a departmental switch from ranibizumab (Lucentis, Genentech, South San Francisco, CA) to bevacizumab (Avastin, Genentech) for the treatment of neovascular age-related macular degeneration (AMD). METHODS: A total of 154 eyes treated for we...
Na minha lista:
| Publicado no: | Digit J Ophthalmol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Massachusetts Eye and Ear Infirmary
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4902645/ https://ncbi.nlm.nih.gov/pubmed/27330464 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5693/djo.01.2015.04.002 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|